Page last updated: 2024-12-10

dexoxadrol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3034023
CHEMBL ID1165411
SCHEMBL ID24683
MeSH IDM0047633

Synonyms (22)

Synonym
PDSP1_000674
PDSP2_000664
(2s)-2-[(4s)-2,2-diphenyl-1,3-dioxolan-4-yl]piperidine
CHEMBL1165411
unii-jy5n9f45ag
(+)-2-(2,2-diphenyl-1,3-dioxolan-4-yl)piperidine
dexoxadrolum [inn-latin]
d-(+)-2,2-diphenyl-4-(2'-piperidyl)-1,3-dioxolane
jy5n9f45ag ,
dexoxadrolum
(+)-alpha-dioxadrol
hsdb 7675
dexoxadrol [inn]
SCHEMBL24683
(+)-.alpha.-dioxadrol
piperidine, 2-((4s)-2,2-diphenyl-1,3-dioxolan-4-yl)-, (2s)-
dexoxadrol [hsdb]
bdbm50130937
DTXSID50912321
Q5268344
AS-16845
AKOS037643549
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)IC50 (µMol)0.00970.00101.88779.8000AID1255979
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)Ki0.01900.00120.48246.0000AID1255983
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)IC50 (µMol)0.00970.00101.99589.8000AID1255979
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)Ki0.01900.00120.62056.0000AID1255983
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
cellular response to amyloid-betaGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
monoatomic cation transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
visual learningGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of calcium ion transport into cytosolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
propylene metabolic processGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of membrane potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein heterotetramerizationGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion homeostasisGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of reactive oxygen species biosynthetic processGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
response to glycineGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
cellular response to amyloid-betaGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
startle responseGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to amphetamineGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
learning or memoryGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
memoryGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
visual learningGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to xenobiotic stimulusGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to woundingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
sensory perception of painGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
neurogenesisGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein catabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
sleepGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
directional locomotionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
negative regulation of protein catabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
dopamine metabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
serotonin metabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of apoptotic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
activation of cysteine-type endopeptidase activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein localization to postsynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calmodulin bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein-containing complex bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
signaling receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
zinc ion bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
cytoplasmGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic vesicleGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
dendriteGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic cleftGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
terminal boutonGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
dendritic spineGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic vesicleGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cytoplasmic vesicle membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
presynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
dendritic spineGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID1462756Displacement of [3H]-di-o-tolylguanidine from sigma 2 receptor in rat liver membranes after 120 mins by scintillation counting analysis2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Replacement of benzylic hydroxy group by vinyl or hydroxymethyl moiety at the 3-benzazepine scaffold retaining GluN2B affinity.
AID1597395Displacement of [3H] ifenprodil from GluN2B/GluN1a (unknown origin) expressed in mouse L(tk-) cell membranes incubated for 120 mins by scintillation counting method
AID599549Displacement of [3H]TCP from NMDA receptor PCP binding site in rat brain2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis of 4-(aminoalkyl) substituted 1,3-dioxanes as potent NMDA and σ receptor antagonists.
AID145233Displacement of [3H]TCP from tissue homogenate preparation of whole rat brain minus cerebellum1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Synthesis, absolute configuration, and molecular modeling study of etoxadrol, a potent phencyclidine-like agonist.
AID599550Displacement of [3H]-(+)-MK801 from NMDA receptor PCP binding site2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis of 4-(aminoalkyl) substituted 1,3-dioxanes as potent NMDA and σ receptor antagonists.
AID1262299Displacement of [3H]-(+)-MK801 from NMDA receptor PCP binding site in pig brain cortex after 150 mins by scintillation counting analysis2015Bioorganic & medicinal chemistry letters, Dec-15, Volume: 25, Issue:24
Benzo[7]annulene-based GluN2B selective NMDA receptor antagonists: Surprising effect of a nitro group in 2-position.
AID1185665Displacement of [3H]-(+)-MK-801 from NMDA receptor PCP binding site in guinea pig brain cortex membranes2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Synthesis and pharmacological evaluation of 5-pyrrolidinylquinoxalines as a novel class of peripherally restricted κ-opioid receptor agonists.
AID1255979Antagonist activity against NR1-1a/NR2A NMDA receptor (unknown origin) expressed in mouse recombinant L(tk-) cells assessed as inhibition of glycine and glutamate induced excitotoxicity incubated for 12 hrs by LDH assay2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Novel Potent N-Methyl-d-aspartate (NMDA) Receptor Antagonists or σ1 Receptor Ligands Based on Properly Substituted 1,4-Dioxane Ring.
AID1369089Displacement of [3H]-(+)-MK-801 from PCP binding site of NMDA receptor in pig brain cortex membranes after 150 mins by solid scintillation counting2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
2-Methyltetrahydro-3-benzazepin-1-ols - The missing link in SAR of GluN2B selective NMDA receptor antagonists.
AID1552398Displacement of [3H]-(+)-MK-801 from NMDA PCP binding site in pig brain cortex membrane incubated for 120 mins by scintillation counting method2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Modification of the 4-phenylbutyl side chain of potent 3-benzazepine-based GluN2B receptor antagonists.
AID1255978Displacement of [3H]MK801 from NMDA receptor PCP binding site in guinea pig brain cortex membranes incubated for 120 mins by scintillation counting method2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Novel Potent N-Methyl-d-aspartate (NMDA) Receptor Antagonists or σ1 Receptor Ligands Based on Properly Substituted 1,4-Dioxane Ring.
AID1255983Binding affinity to NMDA receptor (unknown origin)2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Novel Potent N-Methyl-d-aspartate (NMDA) Receptor Antagonists or σ1 Receptor Ligands Based on Properly Substituted 1,4-Dioxane Ring.
AID1519033Displacement of [3H]-(+)-MK-801 from PCP binding site of NMDA receptor in pig brain cortex membranes after 120 mins by solid scintillation counting method
AID1415571Displacement of [3H](+)-Pentazocine from sigma 1 receptor in guinea pig brain membranes after 120 mins by scintillation counting analysis2017MedChemComm, May-01, Volume: 8, Issue:5
Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID704017Displacement of [3H]-(+)-MK-801 from PCP binding site of NMDA receptor in pig brain cortex2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Enantiomerically pure 1,3-dioxanes as highly selective NMDA and σ₁ receptor ligands.
AID1462755Displacement of [3H](+)-Pentazocine from sigma 1 receptor in guinea pig brain membranes after 120 mins by scintillation counting analysis2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Replacement of benzylic hydroxy group by vinyl or hydroxymethyl moiety at the 3-benzazepine scaffold retaining GluN2B affinity.
AID488105Displacement of [3H]-(+)-MK801 from PCP binding site of NMDA receptor from pig brain cortex after 150 mins by scintillation counting2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Synthesis and NMDA receptor affinity of fluorinated dioxadrol analogues.
AID1174071Displacement of [3H]-(+)-MK-801 from N-methyl D-aspartate receptor phencyclidine binding site in guinea pig brain cortex membranes after 150 mins by scintillation counting method2014Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23
Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.
AID536042Displacement of [3H]-(+)-MK-801 from NMDA receptor phencyclidine binding site in guinea pig brain cortex homogenates after 5 mins by scintillation counting2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Synthesis and SAR studies of chiral non-racemic dexoxadrol analogues as uncompetitive NMDA receptor antagonists.
AID1415567Displacement of [3H]-ifenprodil from GluN2B receptor (unknown origin) expressed in mouse L (tk-) cell membranes after 120 mins by scintillation counting method2017MedChemComm, May-01, Volume: 8, Issue:5
Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID1597396Displacement of [3H]-(+)-MK-801 from NMDA PCP binding site in pig brain cortex membrane at 1 uM incubated for 120 mins by scintillation counting method relative to control
AID1462753Displacement of [3H]-(+)-MK-801 from PCP binding site of NMDA receptor in pig brain cortex2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Replacement of benzylic hydroxy group by vinyl or hydroxymethyl moiety at the 3-benzazepine scaffold retaining GluN2B affinity.
AID1415570Displacement of [3H]-di-o-tolylguanidine from sigma 2 receptor in rat liver membranes after 120 mins by scintillation counting analysis2017MedChemComm, May-01, Volume: 8, Issue:5
Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID1378104Displacement of [3H](+)-MK801 from PCP binding site of NMDA receptor in pig brain cortex membranes after 120 mins by microbeta scintillation counting method2017European journal of medicinal chemistry, Sep-29, Volume: 138Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors.
AID1403512Displacement of [3H]-(+)-MK-801 from NMDA receptor PCP binding site in pig brain cortex membranes incubated for 120 mins measured for 5 mins by scintillation counting method
AID1415568Displacement of [3H]-(+)-MK-801 from PCP binding site of NMDA receptor in pig brain cortex membranes after 90 mins by scintillation counting method2017MedChemComm, May-01, Volume: 8, Issue:5
Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID156972Displacement of [3H]TCP from PCP receptor in tissue preparation of whole rat brain minus cerebellum.1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Analogues of the dioxolanes dexoxadrol and etoxadrol as potential phencyclidine-like agents. Synthesis and structure-activity relationships.
AID1597397Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes incubated for 120 mins by scintillation counting method
AID1597398Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in rat liver membranes incubated for 120 mins by scintillation counting method
AID1272499Binding affinity to PCP binding site of NMDA receptor (unknown origin) by radioligand displacement assay2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Role of the phenolic OH moiety of GluN2B-selective NMDA antagonists with 3-benzazepine scaffold.
AID1462752Displacement of [3H]ifenprodil from human NR1-1a/NR2B receptor expressed in Mouse L(tk-) cell membranes incubated for 120 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Replacement of benzylic hydroxy group by vinyl or hydroxymethyl moiety at the 3-benzazepine scaffold retaining GluN2B affinity.
AID538758Displacement of [3H]-(+)-MK 801 from NMDA receptor phencyclidine binding site in pig brain cortex after 150 mins by scintillation counting2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.
AID600271Displacement of [3H]-(+)-MK801 from NMDA receptor PCP binding site in pig cortex membrane after 90 mins by liquid scintillation counting2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis of 4-(aminoalkyl) substituted 1,3-dioxanes as potent NMDA and σ receptor antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.00)18.7374
1990's1 (5.00)18.2507
2000's0 (0.00)29.6817
2010's18 (90.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.50 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index5.25 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]